Risk stratification based on polyp burden significantly reduced the colonoscopy burden in a prospective 5-year international cohort study.
Preexisting IBDincreases the risk of severe gastrointestinal adverse events in patients treated with checkpoint inhibitors.
Subcutaneous and intravenous vedolizumab formulations are equally effective as maintenance therapy in patients with moderately to severely active ulcerative colitis who had clinical response to intravenous vedolizumab induction therapy.
Post-banding ulcer bleeding is an uncommon but severe complication of esophageal banding. Patients with hepatocellular carcinoma, poor liver function and a low beta-blocker dose have higher risk of post-banding ulcer bleeding. Active bleeding at endoscopy is associated with high mortality, thus aggressive treatment should be considered.
Oesophagus Stomach Duodenum
In a randomized trial comprising 26,771 patients, stress ulcer prophylaxes with proton-pump inhibitors or histamine-2 receptor blockers was associated with comparable rates of hospital mortality, upper gastrointestinal bleeding, infections with Clostridioides difficile and ICU/hospital length of stay.
Cell-free DNA in blood samples from patients who underwent chemoradiotherapy is associated with tumor progression, metastasis and disease-specific survival and may be used to identify patients at high risk for tumor progression.
A retrospective study of 371.813 American veterans indicates that the risk to develop gastric cancer within 20 years following the diagnosis of H. pylori infection is well below 1%. Racial and ethnic minorities as well as smokers have an increased tumor risk which can be reduced by successful eradication therapy.